Diabetes

  • Critical review of economic models, development of initial economic model structure in excel, development of budget impact model and publication in type 2 diabetes
  • Budget impact models for a biosimilar in type 1 and type 2 diabetes mellitus
  • Budget impact model for payer discussions in diabetes
  • Innovative budget impact model in type 2 diabetes
  • Communication on a formulary pack for medication in type 2 diabetes
  • NICE submission and SMC submission for an injectable drug for treatment of type 2 diabetes
  • SMC submission dossier for a treatment for type 2 diabetes
  • Payer strategy analysis of literature search results in type 2 diabetes
  • Payer value proposition and communication for a new remote patient monitoring platform in diabetes
  • Payer value deck in diabetes
  • Payer value slide deck for a biosimilar in diabetes
  • Payer communications in diabetes using data from the short form health survey (SF36)
  • Costing of pre-diabetes care in the US
  • Development of abstracts, posters and a manuscript on the critical review of economic models in diabetes
  • Global value dossier, AMCP and accompanying slide sets for an insulin biosimilar
  • Global value dossier updates, AMCP dossier updates and literature review in diabetes
  • Targeted literature review of the burden of type 2 diabetes mellitus
  • Systematic literature analysis on GLP1 receptor agonists in type 2 diabetes
  • Systematic literature analysis abstracts and white paper development on GLP1 receptor agonists in type 2 diabetes
  • Willingness to pay research in the UK, France and Germany in type 2 diabetes mellitus
  • e-v@luate EVIDENCE platform development for diabetes
  • e-v@luate platform for a payer value deck in type 2 diabetes
  • Manuscript on the barriers to intensification of insulin treatment in patients with type 2 diabetes in the Netherlands
  • Review of an Iranian manuscript on the cost of diabetes
  • Burden of disease in diabetes: Developing journal and conference publications based on market research data
  • Scientific communication for a time trade off (TTO) study in diabetes
  • Scientific communication of a Swedish cost-effectiveness analysis in diabetes
  • Manuscript on patient preference and willingness to pay in diabetes for South Africa
  • Scientific communications for a diabetes patient preference study in the UK
  • Scientific communications on a bolus insulin dosing study
  • Data collection for the use of long-acting insulin in the UK
  • Analysis and summary of outputs of client research with key opinion leaders to support reimbursement submissions and internal communications in diabetes mellitus (type 1 and 2)
  • Key opinion leader testimonials report and German data update in diabetes mellitus (type 1 and 2)
  • Key opinion leader testimonials poster in diabetes
  • Willingness to pay utility study in diabetes
  • Scientific communications for a willingness to pay study in diabetes
  • Frequently asked questions in diabetes
  • Posters regarding long acting insulin usage
  • Attendance at and strategic input into a diabetes workshop
  • Content validation of the paediatric quality of life questionnaire (PEDSQL) for type 1 diabetes mellitus
  • PRO selection, implementation, analysis and reporting on a low carbohydrate (CHO) trial in type 2 diabetes
  • Exploratory analyses and slide deck for a CHO trial in type 2 diabetes
  • PRO selection, implementation, analysis and reporting in type 2 diabetes mellitus
  • Gap analysis, endpoint model and FDA recommendations in type 2 diabetes
  • Recruitment and cognitive debriefing of three patients with type 2 diabetes
  • Indirect comparison of a treatment in type 2 diabetes
  • Systematic review of two treatments for type 2 diabetes
  • Validation of a hypoglycaemia questionnaire in type 2 diabetes
  • Development and validation of a PRO measure of hypoglycaemia, weight gain, tolerability and compliance in type 2 diabetes
  • Blind data review of a clinical trial in type 2 diabetes
  • Clinical trial analysis of a dose ranging study in type 2 diabetes mellitus
  • Analysis of PROs in two clinical trials in type 2 diabetes mellitus
  • Analysis of changes in HbA1C and health-related quality of life (HRQoL) in type 2 diabetes
  • Analysis of hypos versus no hypos in type 2 diabetes mellitus
  • Post-hoc analysis of clinical trial data: Linking clinical outcomes to PRO outcomes in type 2 diabetes mellitus
  • Biostats training and SAS program development for EQ-5D training in type 2 diabetes mellitus
  • Development of a dossier on the novel hypo instruments in type 2 diabetes mellitus
  • HEOR strategy support and study development in type 2 diabetes mellitus
  • Patient interviews in type 2 diabetes for development of a new PRO measure
  • Strategic literature review in type 2 diabetes
  • Literature review and development in type 2 diabetes
  • Consultation on a market research study on patient perceptions of pre-filled insulin pens
  • PRO analysis of a diabetes pre-post meal study
  • Gap analysis to identify the most responsive diabetes PRO measure for clinical trials
  • Validation of a revised symptom checklist in diabetes
  • Validation of the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) for diabetes in Japan
  • Cognitive debriefing on the perceptions about medications diabetes questionnaire (PAM-D)
  • Development of a manuscript on patient perceptions of prefilled insulin delivery devices
  • Database evaluation of costs and outcomes of diabetes treatment
  • Linguistic validation of the Diabetes Symptom Checklist-Revised (DSC-R) into UK English
  • Burden/cost of illness analysis of patient preference for once-weekly treatment in diabetes
  • Literature review examining the benefits of memory function on treatment adherence in diabetes
  • Development of a PRO strategy in diabetes
  • Evaluation of the potential for a satisfaction claim in an insulin product
  • Psychometric validation of a paediatric satisfaction instrument in diabetes
  • Analysis of a prevention clinical trial in diabetes
  • Strategic consulting and training in diabetes to support a client
  • Analysis of a patient qualitative assessment of a diabetic treatment after Ramadan
  • Analysis of clinical trial PRO data to assess patient-perceived and individualised benefit/risk of diabetic treatment